{"title":"溶解双分子层微针在角膜新生血管协同治疗中的高效基质内双重药物递送","authors":"Zhaoliang Zhang, Hui Shi, Jinrun Chen, Ruiling Gu, Yu Li, Shuo Huai, Shan Li, Yuhan Hu, Huiling Wei, Deqing Lin, Lei Lei, Zhishu Bao, Jiaqing Wang, Xingyi Li","doi":"10.1021/acsnano.5c10610","DOIUrl":null,"url":null,"abstract":"Corneal neovascularization (CNV) is one of the major causes of vision impairment and blindness worldwide. Efficient intrastromal drug delivery of antiangiogenic agents is a significant challenge due to the presence of various ocular barriers (<i>i.e</i>., tear barrier, corneal epithelial barrier, <i>etc.</i>). Here, we report a rapidly dissolving bilayer microneedle (MN) patch, combining the anti-VEGF antibody (Ava) with an integrin-targeted anti-inflammatory drug (PF-Y-RGD), achieving synergistic therapy for CNV. Equipped with microscale needle tips, the topically applied MN patches reversibly pierce the corneal epithelium to generate microchannels, bypassing the tear/epithelial barrier and facilitating the transport of payload drugs into the stromal layer of the cornea, which significantly enhances drug bioavailability. Such MN patches exhibit biphasic drug release behavior and are also readily applicable and minimally invasive to impart good ocular tolerance. A rabbit model of CNV reveals that the combination of Ava with PF-Y-RGD in such bilayer MN patches robustly inhibits neovascularization and reduces neovascular areas and the expression of various cytokines (<i>i.e</i>., VEGF, TNF-α, IL-1β, MMP-9) in the cornea. As a strategy for efficient intrastromal drug delivery, this study promises an easy and effective way to treat CNV, which may also lead to approaches for curing various ocular disorders.","PeriodicalId":21,"journal":{"name":"ACS Nano","volume":"340 1","pages":""},"PeriodicalIF":16.0000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Highly Efficient Intrastromal Dual-Drug Delivery by a Dissolving Bilayer Microneedle for Synergistic Therapy against Corneal Neovascularization\",\"authors\":\"Zhaoliang Zhang, Hui Shi, Jinrun Chen, Ruiling Gu, Yu Li, Shuo Huai, Shan Li, Yuhan Hu, Huiling Wei, Deqing Lin, Lei Lei, Zhishu Bao, Jiaqing Wang, Xingyi Li\",\"doi\":\"10.1021/acsnano.5c10610\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Corneal neovascularization (CNV) is one of the major causes of vision impairment and blindness worldwide. Efficient intrastromal drug delivery of antiangiogenic agents is a significant challenge due to the presence of various ocular barriers (<i>i.e</i>., tear barrier, corneal epithelial barrier, <i>etc.</i>). Here, we report a rapidly dissolving bilayer microneedle (MN) patch, combining the anti-VEGF antibody (Ava) with an integrin-targeted anti-inflammatory drug (PF-Y-RGD), achieving synergistic therapy for CNV. Equipped with microscale needle tips, the topically applied MN patches reversibly pierce the corneal epithelium to generate microchannels, bypassing the tear/epithelial barrier and facilitating the transport of payload drugs into the stromal layer of the cornea, which significantly enhances drug bioavailability. Such MN patches exhibit biphasic drug release behavior and are also readily applicable and minimally invasive to impart good ocular tolerance. A rabbit model of CNV reveals that the combination of Ava with PF-Y-RGD in such bilayer MN patches robustly inhibits neovascularization and reduces neovascular areas and the expression of various cytokines (<i>i.e</i>., VEGF, TNF-α, IL-1β, MMP-9) in the cornea. As a strategy for efficient intrastromal drug delivery, this study promises an easy and effective way to treat CNV, which may also lead to approaches for curing various ocular disorders.\",\"PeriodicalId\":21,\"journal\":{\"name\":\"ACS Nano\",\"volume\":\"340 1\",\"pages\":\"\"},\"PeriodicalIF\":16.0000,\"publicationDate\":\"2025-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Nano\",\"FirstCategoryId\":\"88\",\"ListUrlMain\":\"https://doi.org/10.1021/acsnano.5c10610\",\"RegionNum\":1,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Nano","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1021/acsnano.5c10610","RegionNum":1,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Highly Efficient Intrastromal Dual-Drug Delivery by a Dissolving Bilayer Microneedle for Synergistic Therapy against Corneal Neovascularization
Corneal neovascularization (CNV) is one of the major causes of vision impairment and blindness worldwide. Efficient intrastromal drug delivery of antiangiogenic agents is a significant challenge due to the presence of various ocular barriers (i.e., tear barrier, corneal epithelial barrier, etc.). Here, we report a rapidly dissolving bilayer microneedle (MN) patch, combining the anti-VEGF antibody (Ava) with an integrin-targeted anti-inflammatory drug (PF-Y-RGD), achieving synergistic therapy for CNV. Equipped with microscale needle tips, the topically applied MN patches reversibly pierce the corneal epithelium to generate microchannels, bypassing the tear/epithelial barrier and facilitating the transport of payload drugs into the stromal layer of the cornea, which significantly enhances drug bioavailability. Such MN patches exhibit biphasic drug release behavior and are also readily applicable and minimally invasive to impart good ocular tolerance. A rabbit model of CNV reveals that the combination of Ava with PF-Y-RGD in such bilayer MN patches robustly inhibits neovascularization and reduces neovascular areas and the expression of various cytokines (i.e., VEGF, TNF-α, IL-1β, MMP-9) in the cornea. As a strategy for efficient intrastromal drug delivery, this study promises an easy and effective way to treat CNV, which may also lead to approaches for curing various ocular disorders.
期刊介绍:
ACS Nano, published monthly, serves as an international forum for comprehensive articles on nanoscience and nanotechnology research at the intersections of chemistry, biology, materials science, physics, and engineering. The journal fosters communication among scientists in these communities, facilitating collaboration, new research opportunities, and advancements through discoveries. ACS Nano covers synthesis, assembly, characterization, theory, and simulation of nanostructures, nanobiotechnology, nanofabrication, methods and tools for nanoscience and nanotechnology, and self- and directed-assembly. Alongside original research articles, it offers thorough reviews, perspectives on cutting-edge research, and discussions envisioning the future of nanoscience and nanotechnology.